**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 38908**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Observational Study***

**Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma**

An Y *et al*. Prognosis of hepatocellular carcinoma

Yang An, Song Gao, Wen-Chao Zhao, Bao-An Qiu, Nian-Xin Xia, Peng-Jun Zhang, Zhen-Ping Fan

**Yang An, Wen-Chao Zhao, Bao-An Qiu, Nian-Xin Xia,** Department of Hepato-Biliary-Pancreatic Surgey, Navy General Hospital of Chinese People’s Liberation Army, Beijing 100048, China

**Song Gao, Peng-Jun Zhang,** Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing 100142, China

**Zhen-Ping Fan,** Liver Disease Center for Cadre Medical Care, Beijing 302 Military Hospital, Beijing 100039, China

**ORCID number:** Yang An (0000-0002-2515-4562); Song Gao (0000-0002-7466-3654); Wen-Chao Zhao (0000-0002-1445-376X); Bao-An Qiu (0000-0001-9474-3101); Nian-Xin Xia (0000-0002-3785-1381); Peng-Jun Zhang (0000-0002-7391-2495); Zhen-Ping Fan (0000-0001-5725-5758).

**Author contributions:** An Y, Gao S, Fan ZP, and Zhang PJ designed the study; An Y, Gao S, Zhao WC, and Xia NX performed the research; An Y, Gao S, Qiu BA, Fan ZP, and Zhang PJ analyzed the date; An Y and Gao S wrote the paper; Fan ZP and Zhang PJ revised the manuscript for final submission; An Y and Gao S contributed equally to this study; Fan ZP and Zhang PJ are the co-corresponding authors.

**Supported by** the National Key R&D Program of China, No. 2016YFC0106604; and National Natural Science Foundation of China, No. 81502591.

**Institutional review board statement:** The study was reviewed and approved by the Peking University Cancer Hospital & Institute review board.

**Informed consent statement:** All study participants or their legal guardian provided written informed consent prior to study enrollment.

**Conflict-of-interest statement:** We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The ARRIVE Guidelines have been adopted in our manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Zhen-Ping Fan, MD,** **Doctor,** The Liver Disease Center for Cadre Medical Care, Beijing 302 Military Hospital, Xi Si Huan Zhong Road 100, Beijing 100039, China. fanzp302@126.com

**Telephone:** +86-1-66933466

**Fax:** +86-1-63879735

**Received:** March 22, 2018

**Peer-review started:** March 22, 2018

**First decision:** April 10, 2018

**Revised:** April 14, 2018

**Accepted:** June 2, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To understand the cellular and molecular changes in peripheral blood that can lead to the development of hepatocellular carcinoma (HCC) and provide new methods for its diagnosis and treatment.

***METHODS***

Peripheral blood mononuclear cells were isolated from the peripheral blood of HCC patients and normal controls and then analyzed by flow cytometry. The percentage of transforming growth factor-β (TGF-β)+ regulatory cells (Tregs) in the peripheral blood was measured, and the expression of TGF-β was also determined. Then, the relationship between the changes and the five-year survival of patients was analyzed. In addition, recombinant human TGF-β (rhTGF-β) and recombinant human interleukin-6 were added to stimulate the cultured cells, and their effects on HCC were evaluated.

***RESULTS***

The expression of TGF-β and the percentage of TGF-β+ Tregs in the peripheral blood of HCC patients increased significantly compared with normal controls. Compared with the low TGF-β expression group, the high TGF-β expression group had a significantly lower five-year survival rate, and the same result was found in the two TGF-β+ Treg groups, suggesting that TGF-β and TGF-β+ Tregs were negatively correlated with the overall survival of the patients. In addition, rhTGF-β promoted the growth of tumor cells and induced high expression levels of IL-6, which further promoted tumor proliferation.

***CONCLUSION***

The results showed that TGF-β may promote tumor growth and proliferation by inducing the production of IL-6, and TGF-β and TGF-β+ Tregs may serve as new markers for predicting a poor prognosis in HCC.

**Key words:** Hepatocellular carcinoma; Transforming growth factor-β; Regulatory cells; Peripheral blood mononuclear cells; Interleukin-6

**©The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We aimed to understand the cellular and molecular changes in peripheral blood of hepatocellular carcinoma (HCC) and provide new methods for its diagnosis and treatment. The results showed that transforming growth factor-β (TGF-β) may promote tumor growth and proliferation by inducing the production of interleukin-6, and TGF-β and TGF-β+ regulatory cells may serve as new markers for predicting poor prognosis of HCC.

An Y, Gao S, Zhao WC, Qiu BA, Xia NX, Zhang PJ, Fan ZP. Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the second leading cause of cancer deaths in the word[[1](#_ENREF_1)]. According to the WHO, approximately 788000 people die from primary liver cancer each year. It has been reported that the morbidity and mortality of HCC in China are very high[[2](#_ENREF_2),[3](#_ENREF_3)]. Improvements have been made in HCC treatment, which includes surgery, chemotherapy, radiation therapy and ablation; however, HCC still has a poor prognosis because of recurrence and tumor metastasis[[4](#_ENREF_4)].

Studies have shown that tumors can establish the tumor microenvironment by regulating lymphocytes, which play an important role in tumor development through inflammatory immunity[[5](#_ENREF_5),[6](#_ENREF_6)]. Tumor cells can inhibit the function of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment through inhibitory signaling pathways in the immune system; this process results in the immunosuppression of tumors[[7](#_ENREF_7),[8](#_ENREF_8)]. Tumors can also accumulate infiltrated immune cells to inhibit anti-tumor effects by secreting immunosuppressive factors, such as interleukin-2 (IL-2), transforming growth factor-β (TGF-β), matrix metalloproteinase (MMP), vascular endothelial growth factor (VEGF) and interleukin-10 (IL-10), into the microenvironment[[9](#_ENREF_9)]. It has also been reported that tumors can affect the proliferation, migration, and survival of cancer cells through the inflammatory effects of immune cells[[10](#_ENREF_10),[11](#_ENREF_11)]. It is well known that regulatory cells (Tregs) can promote the development of tumors by inhibiting immune surveillance[[12](#_ENREF_12)]. The knockdown of forkhead box P3 (Foxp3), which is specifically expressed in Tregs, can reduce the immunosuppression of Tregs, which can suppress tumor growth in mice with HCC[[13](#_ENREF_13)]. Therefore, understanding the immune status, especially the inflammatory state of cancer, may provide a new method of immunomodulation for the treatment of cancer.

Studies have shown that TGF-β is one of the key products of Tregs[[14](#_ENREF_14)], and it maintains the internal stability of stem cells and promotes fibrosis, embryonic development, tissue repair, cell proliferation and differentiation, and immune regulation[[15](#_ENREF_15)]. Tumor-associated TGF-β negatively regulates the host immune response through the following mechanisms[[16](#_ENREF_16),[17](#_ENREF_17)]. First, tumor-associated TGF-β mediates the differentiation of Th1 cells to Th2 cells *via* IL-10. Second, tumor-associated TGF-β directly inhibits M1 giant macrophages and the antitumor immune responses mediated by Th1. Third, tumor-associated TGF-β inhibits the functions of CD8+ T lymphocytes, NK cells, and dendritic cells, which have cytotoxic effects. Fourth, tumor-associated TGF-β produces CD4+ CD25+ Tregs to inhibit the function of other lymphocyte groups[[18](#_ENREF_18)]. Finally, tumor-associated TGF-β promotes M2 macrophages, which can produce reactive oxygen species to promote tumor development through secreting immunosuppressive cytokines (TGF-β and IL-10), angiogenic factors (CXC chemokines, MMP-9 and VEGF), proinflammatory cytokines (IL-1, TNF-α, and IL-6) and tumor growth factors. TGF-β has a dual role in the development of tumors, and it can promote the invasion and metastasis of tumor cells mainly by regulating the immune system and tumor microenvironment[[16](#_ENREF_16)].

**MATERIALS AND METHODS**

***Patients and blood sample collection***

We included 100 patients with HCC who were diagnosed at Beijing Cancer Hospital between 2010 and 2014, and we included 36 healthy subjects without any signs of disease. Blood samples were collected before any treatment. According to the 2002 American Joint Committee on Cancer (AJCC) staging criteria, the samples were divided into two groups: early stage (stages I and II) and late stage (stages III and IV). All patient information is shown in Table 1. Of the HCC patients, 63 were followed up until death or until July 31, 2017. The median follow-up time was 40.3 mo (mean ± SD: 40.3 ± 11.6 mo). All participants provided informed consent, and the study was approved by the Ethics Committee of Beijing Cancer Hospital.

***Measurement of cytokines***

Whole blood samples from all patients and normal controls were centrifuged at 3000 g for 10 min to collect the serum; then, the concentrations of TGF-β and IL-6 were measured by ELISA kits (eBioscience) and human inflammation CBA kits (BD Biosciences), respectively.

***Collection and culture of PBMCs***

Density centrifugation of 5 mL of heparinized peripheral blood from patients with HCC and normal controls was performed to obtain PBMCs. There were 2 steps to the horizontal centrifugation: 2000 r/min for 20 min and 15000 r/min for 10 min[[19](#_ENREF_19)]. The final cell pellet was resuspended and cultured in the appropriate amount of 1640 medium containing 10% fetal bovine serum. The cells were counted using a microscope, and the cell concentration was adjusted to 2 × 106/mL. A total of 200 μL of each cell suspension was pipetted into a 96-well flat bottom cell culture plate, and 1 μL of 10 μg/mL PMA, 2 μL of 100 μg/mL IO and 2 μL of 300 μg/mL BFA were added. The cells were incubated at 37°C with 5% CO2 for 4-5 h and then subjected to flow cytometry and analysis.

***Flow cytometry analysis***

CD4 and CD3 antibodies were added to label the cells. A Foxp3 antibody was also added to detect the Tregs. A constant volume of 100 μL of PBS was used for the flow cytometry analyses, which were performed on a BD FACSCalibur system.

***Cell culture***

HepG2, PLHC-1, and LMH cell lines were selected for cell culture, and all three cell lines were cultured in an incubator at 37 °C and 5% CO2. rhTGF-β or rhIL-6 (PeproTech, United States) was added to three 6-well plates containing the three HCC cell lines to stimulate the tumor cells for 24-48 h according to the manufacturer’s instructions. To analyze the proliferation rates, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and cell counting were performed.

***Statistical analysis***

Statistical analyses were performed using GraphPad Prism 5.0 (San Diego, CA, United States). The data are expressed as the mean ± SD. T-tests were used to assess the differences between groups. The overall survival rates of HCC were analyzed with Kaplan-Meier curves. All tests were two-tailed, and *P* < 0.05 was considered to be statistically significant.

**RESULTS**

***Increased expression of TGF-β in the serum of liver cancer patients***

We measured the levels of TGF-β in the serum of 100 patients with HCC and 36 normal controls using ELISAs. The results showed that the serum levels of TGF-β were significantly higher in the HCC patients (225.82 ± 48.93 ng/mL) than in the normal controls (57.29 ± 11.70 ng/mL, *P* < 0.0001, Figure 1).

***Tregs are associated with the progression of HCC***

Studies have shown that TGF-β is one of the key products of Tregs[[14](#_ENREF_14)]. We performed flow cytometry analyses of 100 HCC samples and 36 normal controls, and the results clearly indicated TGF-β-expressing cell populations in the PBMCs and Tregs. The population of TGF-β-expressing cells in the Tregs was analyzed by flow cytometry, and Figure 2A is representative of all the data figures. A statistical analysis showed that the proportion of TGF-β+ Tregs was significantly higher in HCC patients (14.14 ± 6.02%) than in normal controls (3.00 ± 1.43%, *P* <0.001, Figure 2B). In fact, the percentage of TGF-β+ Tregs was significantly higher in HCC patients in advanced stages (15.47 ± 6.95%) than in HCC patients in early stages (12.70 ± 4.37%) and normal controls (Figure 2C), suggesting a possible positive correlation between the presence of TGF-β+ Tregs and tumor progression.

***Increased levels of TGF-β and TGF-β+ Tregs may predict a poor prognosis for HCC***

In this study, we analyzed the effects of high and low levels of peripheral blood TGF-β and TGF-β+ Tregs on the five-year survival rate of 63 patients with HCC who were followed up. The results showed that compared to the low TGF production group, the high TGF-β production group had a significantly lower overall survival rate (Figure 3A, 31.0% *vs* 53.0%, *P* = 0.010). Compared with the low TGF-β+ Tregs group, the high TGF-β+ Tregs group had a significantly higher death hazard rate (Figure 3B, 38.0% *vs* 53.5%, *P* = 0.047). The results suggest that the overall survival of the patients with HCC is negatively correlated with the levels of TGF and Tregs.

***TGF-β activates IL-6 production in HCC to promote tumor growth***

Three human HCC cell lines, namely, HepG2, PLHC-1, and LMH, were selected for this study. We added rhTGF-β to stimulate the three HCC cell lines and then detected changes in their biological function. Compared with the untreated group, all three HCC cell lines treated with 100 ng/mL rhTGF-β for 48 h showed significant cell proliferation afterwards (Figure 4A). We also examined IL-6 levels in the cell supernatants and found that IL-6 levels were significantly higher in the rhTGF-β-treated cell supernatants than in the untreated cell supernatants (Figure 4B). Furthermore, the three HCC cell lines were treated with rhIL-6, and significantly higher cell proliferation rates were found in all three HCC cell lines treated with rhIL-6 than in the untreated cells (Figure 4C). These results indicate that TGF-β has the potential to promote HCC cell proliferation, and it can also mediate IL-6 production to further promote tumor cell proliferation.

**DISCUSSION**

This study demonstrated that the levels of TGF-β and TGF-β+ Tregs in the peripheral blood were significantly higher in HCC patients than in normal controls, and these levels were negatively associated with the five-year survival of HCC patients. At the same time, TGF may promote the development of tumors by inducing IL-16 expression, suggesting that peripheral TGF-β and TGF-β+ Tregs can be used as potential markers to predict a poor prognosis in HCC patients.

Understanding the immune status, especially the inflammatory state of cancer, may provide a new method of immunomodulation for the treatment of cancer. In the early stages of cancer, or the stages of hepatocellular degeneration and injury, abnormally high expression levels of insulin-like growth factor II (IGF-II) have been observed, which can be an indicator for the early diagnosis of liver cancer, and liver injury may be caused by the abnormal activation of the IGF-II gene by the cancer-causing factor diethylnitrosamine[[20](#_ENREF_20),[21](#_ENREF_21)]. It was also reported that high expression levels of IGF-II in the serum and livers of rats are events in the early and advanced stages of the occurrence and development of liver cancer[[21](#_ENREF_21)]. Some studies have shown that vascular endothelial growth factor (VEGF) is more sensitive for the prediction of liver cancer in patients with cirrhosis related to hepatitis C virus (HCV), and VEGF expression is related to tumor vascular invasion[[22](#_ENREF_22)]. VEGF expression has been associated with tumor diameter and lymph node metastasis, and its positive rate is 72.0% in HCC. Therefore, VEGF may be applied for evaluating hematopoietic liver cancer metastasis and predicting HCC with HCV. It has been reported that the expression levels of Golgi protein 73 (GP73) are significantly higher in HCC serum samples than in control serum samples. GP73 has high specificity and sensitivity for diagnosing HCC and is expected to become another liver cancer marker[[23](#_ENREF_23)]. The expression levels of des-gamma-carboxy prothrombin (DCP) are affected by the pathological type and stage of tumors and the type of hepatic lesions in HCC. Its ability to diagnose HCC is better than that of alpha fetoprotein (AFP) and AFP-L3, which are first-line clinical tumor markers, and it can be used as an early indicator for diagnosing liver cancer[[24](#_ENREF_24),[25](#_ENREF_25)].

Tregs are a subpopulation of T lymphocytes that have unique in vivo functions; Tregs can secrete IL-4, IL-10 and TGF-β and inhibit effector T cells, and they are involved in autoimmune diseases, transplantation immunity, and tumor immunity[[26](#_ENREF_26)]. According to the biological function of Th cells and Tregs, there is a dynamic balance between the two types of immune cells. The disruption of the balance between proinflammatory Th17 cells and suppressor Tregs is a key factor in the development of inflammation, autoimmune diseases, and tumors, and their expression levels in different immune response types are not the same. Recent studies have shown that tumor cells secrete multiple factors that can induce the production of Tregs[[27](#_ENREF_27),[28](#_ENREF_28)]. Thl7 cells are negatively correlated with tumor progression because of the reduction in their number and proportion, whereas Tregs are positively correlated since their quantity and proportion are increased[[29](#_ENREF_29)]; these data are consistent with the findings of our study. Tregs can suppress immune surveillance during tumor development in a mouse model of carcinogen-induced sarcoma[[30](#_ENREF_30)]. Tregs can also be considered as the main component of tumor evasion of the host immune system and thus can serve as an indicator of poor prognosis and even as a target for immunotherapy[[31-33](#_ENREF_31)].

In sum, our study demonstrated that the levels of expression of TGF-β and TGF-β+ Tregs in the peripheral blood of HCC patients were significantly increased and were related to the progression of HCC and the five-year survival of patients. This suggests that peripheral blood TGF-β levels can serve as a potential indicator of poor prognosis for HCC and provide a more effective method for the diagnosis and treatment of HCC.

**ARTICLES HIGHLIGHTS**

***Research background***

Although the treatment of hepatocellular carcinoma (HCC) has been improved, including surgery, chemotherapy, radiation therapy and ablation, however, it always retain a poor prognosis because of the recurrence and tumor metastasis.

***Research motivation***

To understand the immune status especially the inflammatory state of cancer, may provide a new method of immunomodulation for the treatment of cancer, and may have potential evaluation for the prognosis of HCC.

***Research objectives***

To understand the cellular and molecular changes in peripheral blood that can lead to the development of HCC and provide new methods for its diagnosis and treatment.

***Research methods***

Peripheral blood mononuclear cells were isolated from peripheral blood of HCC patients and normal controls and then be analyzed by flow cytometry. The percentage of TGF-β+ Treg cells in peripheral blood was measured and the expression of TGF-β was also detected. Analyze the relationship between the changes and the five-year survival of patients. In addition, recombinant human TGR-β and recombinant human IL-6 were added respectively to stimulate the cultured cells to evaluate its effect on HCC.

***Research results***

The expression of TGF-β and percentage of TGF-β+ Treg cells in peripheral blood in HCC patients increased significantly, comparing with normal controls. Compared with the low TGF-β expression group, the five-year survival rate was significantly lower in the high TGF-β expression group, and had the same result was in the two TGF-β+ Treg groups, suggesting that TGF-β and TGF-β+ Treg cells were negatively correlated with the overall survival of the patients. In addition, recombinant human TGF-β can promote the growth of tumor cells and induce the high expression of IL-6 which can further promote tumor proliferation.

***Research conclusions***

The results showed that TGF-β may promote tumor growth and proliferation by inducing the production of IL-6, and TGF-β and TGF-β+ Treg cells may serve as new markers for predicting poor prognosis of HCC.

***Research perspectives***

Our study provided a novel insight to understand the cellular and molecular changes in peripheral blood of HCC and provide new methods for its diagnosis and treatment.

**REFERENCES**

1 **Llovet JM**, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. *Nat Rev Clin Oncol* 2015; **12**: 436 [PMID: 26099984 DOI: 10.1038/nrclinonc.2015.121]

2 **Han KH**, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. *Oncology* 2011; **81** Suppl 1: 158-164 [PMID: 22212951 DOI: 10.1159/000333280]

3 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

4 **Maluccio M**, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. *CA Cancer J Clin* 2012; **62**: 394-399 [PMID: 23070690 DOI: 10.3322/caac.21161]

5 **Ganss R**, Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. *Cancer Res* 1998; **58**: 4673-4681 [PMID: 9788621]

6 **Coussens LM**, Werb Z. Inflammation and cancer. *Nature* 2002; **420**: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]

7 **Wherry EJ**. T cell exhaustion. *Nat Immunol* 2011; **12**: 492-499 [PMID: 21739672]

8 **Chen X**, Liang H, Guan D, Wang C, Hu X, Cui L, Chen S, Zhang C, Zhang J, Zen K, Zhang CY. A combination of Let-7d, Let-7g and Let-7i serves as a stable reference for normalization of serum microRNAs. *PLoS One* 2013; **8**: e79652 [PMID: 24223986 DOI: 10.1371/journal.pone.0079652]

9 **Beatty GL**, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. *Clin Cancer Res* 2015; **21**: 687-692 [PMID: 25501578 DOI: 10.1158/1078-0432.CCR-14-1860]

10 **Lin WW**, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. *J Clin Invest* 2007; **117**: 1175-1183 [PMID: 17476347 DOI: 10.1172/JCI31537]

11 **Douglas WG**, Tracy E, Tan D, Yu J, Hicks WL Jr, Rigual NR, Loree TR, Wang Y, Baumann H. Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. *Mol Cancer Res* 2004; **2**: 585-593 [PMID: 15498933]

12 **Linehan DC**, Goedegebuure PS. CD25+ CD4+ regulatory T-cells in cancer. *Immunol Res* 2005; **32**: 155-168 [PMID: 16106066 DOI: 10.1385/IR:32:1-3:155]

13 **Shi C**, Zhang Y, Yang H, Dong T, Chen Y, Xu Y, Yang X, Liu P. Ultrasound-targeted microbubble destruction-mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function. *Exp Ther Med* 2018; **15**: 31-38 [PMID: 29387180 DOI: 10.3892/etm.2017.5421]

14 **Glebezdina NS**, Olina AA, Nekrasova IV, Kuklina EM. Role of Endogenous Melatonin in the Regulation of Th17/Treg Balance during Pregnancy. *Bull Exp Biol Med* 2018; **164**: 462-465 [PMID: 29504099 DOI: 10.1007/s10517-018-4013-1]

15 **Patman G**. Liver cancer: TGF-β and cholangiocarcinoma. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 2-3 [PMID: 26669764 DOI: 10.1038/nrgastro.2015.218]

16 **Achyut BR**, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. *Gastroenterology* 2011; **141**: 1167-1178 [PMID: 21839702 DOI: 10.1053/j.gastro.2011.07.048]

17 **Derynck R**, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003; **425**: 577-584 [PMID: 14534577 DOI: 10.1038/nature02006]

18 **Shen Y**, Wei Y, Wang Z, Jing Y, He H, Yuan J, Li R, Zhao Q, Wei L, Yang T, Lu J. TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. *Cell Physiol Biochem* 2015; **35**: 1623-1632 [PMID: 25824460 DOI: 10.1159/000373976]

19 **Kryczek I**, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. *Blood* 2009; **114**: 1141-1149 [PMID: 19470694 DOI: 10.1182/blood-2009-03-208249]

20 **Ikeda Y**, Kajiyama K, Yamashita Y, Ikegami T, Uchiyama H, Soejima Y, Kawanaka H, Ikeda T, Morita M, Oki E, Saeki H, Suehiro T, Mimori K, Sugimachi K, Shirabe K, Maehara Y. Differential expression of insulin-like growth factor 1 in human primary liver cancer. *Fukuoka Igaku Zasshi* 2013; **104**: 334-338 [PMID: 24511663]

21 **Wong VW**, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. *Int J Cancer* 2009; **124**: 2766-2770 [PMID: 19267406 DOI: 10.1002/ijc.24281]

22 **Mukozu T**, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. *Anticancer Res* 2013; **33**: 1013-1021 [PMID: 23482775]

23 **Mao Y**, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. *Gut* 2010; **59**: 1687-1693 [PMID: 20876776 DOI: 10.1136/gut.2010.214916]

24 **Marrero JA**, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. *Hepatology* 2003; **37**: 1114-1121 [PMID: 12717392 DOI: 10.1053/jhep.2003.50195]

25 **Volk ML**, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. *Cancer Biomark* 2007; **3**: 79-87 [PMID: 17522429]

26 **Ernerudh J**, Berg G, Mjösberg J. Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. *Am J Reprod Immunol* 2011; **66** Suppl 1: 31-43 [PMID: 21726336 DOI: 10.1111/j.1600-0897.2011.01049.x]

27 **Maturu P**, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. *Neoplasia* 2017; **19**: 237-249 [PMID: 28254151 DOI: 10.1016/j.neo.2016.07.009]

28 **Holmgaard RB**, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. *Cell Rep* 2015; **13**: 412-424 [PMID: 26411680 DOI: 10.1016/j.celrep.2015.08.077]

29 **Chen X**, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4+CD25+ regulatory T cells in tumor immunity. *Int Immunopharmacol* 2016; **34**: 244-249 [PMID: 26994448 DOI: 10.1016/j.intimp.2016.03.009]

30 **Betts G**, Twohig J, Van den Broek M, Sierro S, Godkin A, Gallimore A. The impact of regulatory T cells on carcinogen-induced sarcogenesis. *Br J Cancer* 2007; **96**: 1849-1854 [PMID: 17565340 DOI: 10.1038/sj.bjc.6603824]

31 **Shou J**, Zhang Z, Lai Y, Chen Z, Huang J. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. *BMC Cancer* 2016; **16**: 687 [PMID: 27566250 DOI: 10.1186/s12885-016-2732-0]

32 **Xu W**, Liu H, Song J, Fu HX, Qiu L, Zhang BF, Li HZ, Bai J, Zheng JN. The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer. *J Cancer Res Clin Oncol* 2013; **139**: 1845-1852 [PMID: 24005418 DOI: 10.1007/s00432-013-1500-7]

33 **Mizukami Y**, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. *Br J Cancer* 2008; **98**: 148-153 [PMID: 18087278 DOI: 10.1038/sj.bjc.6604149]

**P-Reviewer:** Czubkowski P, Gobejishvili L, TatsuyaO **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinicopathological characteristics of 100 patients with hepatocellular carcinoma *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **HCC (*n* = 100)** | **Normal controls (*n* = 36)** | ***P* value** |
| Average age (yr) | 53.33 | 50.36 | 0.16 |
| Age (yr) |  |  | 0.61 |
| ≤ 50 | 45 (45.0) | 18 (50.0) |  |
| > 50 | 55 (55.0) | 18 (50.0) |  |
| Sex |  |  | 0.68 |
| Male | 65 (65.0) | 22 (61.1) |  |
| Female | 35 (35.0) | 14 (38.9) |  |
| T classification |  |  |  |
| T1 | 12 (12.0) |  |  |
| T2 | 36 (36.0) |  |  |
| T3 | 42 (42.0) |  |  |
| T4 | 10 (10.0) |  |  |

HCC: Hepatocellular carcinoma.



**Figure 1 Levels of transforming growth factor-β in the serum of hepatocellular carcinoma patients and normal controls.** a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. TGF-β: transforming growth factor-β; HCC: Hepatocellular carcinoma.

**A**



**B C**



**Figure 2 Increase of transforming growth factor-β+ regulatory cells in the serum of hepatocellular carcinoma patients.** A: Representative plots for identification of the TGF-β+ Treg cells producing cells in PBMC; B: Analysis of the frequency of TGF-β+ Treg cell from the PBMCs of healthy donors in comparison to HCC patients; C: Analysis of the frequency of TGF-β+ Treg cell from the PBMCs of healthy donors in comparison to HCC patients with tumors at different stages. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. TGF-β: Transforming growth factor-β; Treg: Regulatory cells; HCC: Hepatocellular carcinoma.

**A**



**B**



**Figure 3** **Level of transforming growth factor-β and transforming growth factor-β+ regulatory cells affect five-year survival for hepatocellular carcinoma patients.** The five-year survival rates for HCC patients with a high and low level of TGF-β (a), and TGF-β+ Treg cells (b) in their PBMCs. The survival rates were determined using the Kaplan-Meier method (log-rank test). TGF-β: Transforming growth factor-β; Treg: Regulatory cells; HCC: Hepatocellular carcinoma.

A



B

C



**Figure 4 Transforming growth factor-β can promote the proliferation of tumour cells and induce the increase of the level of interleukin-6 followed by cell proliferation in the hepatocellular carcinoma cell lines production of IL-6.** A: The cell numbers of the three HCC cell lines after treated with 100 ng/mL rhTGF-β for 48 h. B: The three HCC culture supernatants were analyzed for protein levels of IL-6 after treatment with rhTGF-β for 48 h using ELISA. C: The three HCC cell lines were treated with or without rhIL-6 for 48 h, and cell proliferation was determined by MTT assay. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. TGF-β: Transforming growth factor-β; Treg: Regulatory cells; HCC: Hepatocellular carcinoma.